IkB kinase/nuclear factor kB (IKK/NF-kB) signaling exhibits important yet opposing functions in hepatocarcinogenesis. Mice lacking NEMO in liver parenchymal cells (LPC) spontaneously develop steatohepatitis and hepatocellular carcinoma (HCC) suggesting that NF-kB prevents liver disease and cancer. Here, we show that complete NF-kB inhibition by combined LPC-specific ablation of RelA, c-Rel, and RelB did not phenocopy NEMO deficiency, but constitutively active IKK2-mediated NF-kB activation prevented hepatocellular damage and HCC in NEMO LPC-KO mice. Knock-in expression of kinase inactive receptor-interacting protein kinase 1 (RIPK1) prevented hepatocyte apoptosis and HCC, while RIPK1 ablation induced TNFR1-associated death domain protein (TRADD)-dependent hepatocyte apoptosis and liver tumors in NEMO LPC-KO mice, revealing distinct kinase-dependent and scaffolding functions of RIPK1. Collectively, these results show that NEMO prevents hepatocarcinogenesis by inhibiting RIPK1 kinase activity-driven hepatocyte apoptosis through NF-kB-dependent and -independent functions.
Correspondence pasparakis@uni-koeln. de In Brief Kondylis et al. identify an NF-kBindependent function of NEMO in controlling RIPK1 kinase activitydependent apoptosis of hepatocytes and thus hepatocarcinogenesis. NEMOmediated NF-kB activity and kinase activity-independent scaffold function of RIPK1 also regulate hepatocyte apoptosis.
INTRODUCTION
Liver cancer is the fifth most common cancer in men and the seventh in women (El-Serag, 2011; Shariff et al., 2009 ). Hepatocellular carcinoma (HCC), the most prominent primary liver cancer, usually develops in the presence of cirrhosis and chronic inflammatory conditions resulting from hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, alcoholic and non-alcoholic
Significance
Pathways regulating cell survival, cell death, and inflammation play a key role in the maintenance of liver homeostasis and the pathogenesis of chronic liver disease and cancer. Caspase-dependent apoptosis and receptor-interacting protein (RIP) kinase-dependent necroptosis are key pathways of programmed cell death and have been implicated in disease pathogenesis. Here, we reveal a RIP kinase 3 (RIPK3)-independent function of RIP kinase 1 (RIPK1) in mediating hepatocyte apoptosis and triggering chronic hepatitis and HCC development. This function of RIPK1 depends on its kinase activity and is controlled by nuclear factor kB (NF-kB)-dependent and NF-kB-independent NEMO functions. These results identify the interplay between NEMO and RIPK1 as a key mechanism that is essential for hepatocyte survival and the prevention of chronic liver damage leading to hepatocarcinogenesis. (legend continued on next page) steatohepatitis, and aflatoxin-mediated toxicity (Shariff et al., 2009 ). Due to the limited treatment options, HCC is the third most common cause for cancer-related deaths worldwide (ElSerag, 2011; Shariff et al., 2009) . Therefore, there is an urgent need to better understand the mechanisms contributing to the pathogenesis of chronic liver inflammation and HCC in order to identify possible preventive strategies and therapeutic targets. Death receptors, such as tumor necrosis factor receptor 1 (TNFR1), regulate cell death and inflammation and are implicated in the pathogenesis of acute and chronic liver diseases and in liver cancer (Schattenberg et al., 2011; Wang, 2014) . Upon stimulation, TNFR1 activates proinflammatory nuclear factor kB (NF-kB) and mitogen-activated protein (MAP) kinase cascades through a receptor-proximal signaling complex (complex I), composed of TNFR1-associated death domain protein (TRADD), receptor-interacting protein kinase 1 (RIPK1), as well as the E3 ubiquitin ligases TNF receptor-associated factor 2 (TRAF2), cellular inhibitors of apoptosis 1 (cIAP1) and cellular inhibitors of apoptosis 2 (cIAP2), and the linear ubiquitin chain assembly complex (LUBAC) (Micheau and Tschopp, 2003; Walczak et al., 2012) . In sensitized cells (e.g., upon NF-kB inhibition), complex I dissociates from the receptor and recruits Fas-associated via death domain protein (FADD) and caspase-8 to induce apoptosis (Micheau and Tschopp, 2003) . When caspase-8 is inhibited, TNFR1 triggers necroptosis via receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like protein (MLKL) (Vanden Berghe et al., 2014; Weinlich et al., 2011) . RIPK1 determines the outcome of TNFR1 signaling by inducing pro-survival and proinflammatory signaling via kinaseindependent scaffolding functions, but also apoptosis or necroptosis through its kinase activity (Christofferson et al., 2014; Pasparakis and Vandenabeele, 2015) .
The IkB kinase (IKK)/NF-kB pathway regulates cell survival, inflammation, and cancer (Ben-Neriah and Karin, 2011; Hayden and Ghosh, 2012) and is implicated in the pathogenesis of hepatitis and HCC (Luedde and Schwabe, 2011; Sun and Karin, 2008) . Mammalian cells express five NF-kB transcription factors, RelA/p65, RelB, c-Rel, p50/p105, and p52/p100. RelA, c-Rel, and RelB contain transactivation domains and are capable to activate gene transcription. In resting cells, NF-kB dimers are kept inactive by association with inhibitory IkB proteins. Upon cell stimulation, the IKK complex, consisting of the IKK1/IKKa and IKK2/IKKb kinases and the NEMO/IKKg regulatory subunit, phosphorylates IkB proteins targeting them for proteasomal degradation. Consequently, NF-kB dimers accumulate in the nucleus where they regulate the transcription of many genes involved in inflammation, cell growth, cell survival, and proliferation (Hayden and Ghosh, 2012; Pasparakis, 2009; Perkins, 2012) .
Mouse model studies revealed important but contradictory functions of IKK/NF-kB signaling in liver carcinogenesis. IkBa super-repressor-mediated NF-kB inhibition in hepatocytes delayed HCC progression but not tumor initiation in the Mdr2 À/À mouse model of inflammation-driven liver carcinogenesis by counteracting TNF-mediated tumor promotion in hepatocytes (Pikarsky et al., 2004) . In addition, hepatocyte-specific ablation of IKK2 prevented hepatitis and liver tumorigenesis induced by transgenic overexpression of lymphotoxin a/b by inhibiting LTb receptor-mediated expression of chemokines and cytokines (Haybaeck et al., 2009) . These reports support a predominantly tumor-promoting function of NF-kB in hepatocytes. In contrast, other studies revealed tumor-suppressing functions of IKK/NF-kB signaling in the liver. In a mouse model of diethylnitrosamine (DEN)-induced hepatocarcinogenesis, hepatocyte-specific ablation of IKK2 resulted in increased tumor load due to enhanced DEN-induced liver damage and compensatory proliferation of IKK2-deficient hepatocytes (Maeda et al., 2005) . Mice with liver parenchymal cell (LPC)-specific ablation of NEMO (NEMO LPC-KO ) spontaneously developed chronic steatohepatitis and HCC, further supporting a tumor suppressing function of IKK/NF-kB signaling in hepatocytes (Luedde et al., 2007) . The development of hepatitis and HCC in NEMO LPC-KO mice is triggered by FADD-and caspase-8-dependent apoptosis of NEMO-deficient hepatocytes (Ehlken et al., 2014; Liedtke et al., 2011; Luedde et al., 2007) . However, the molecular mechanisms by which NEMO inhibits hepatocyte apoptosis, hepatitis and HCC remain poorly understood. Here, we addressed the role of NF-kB and RIPK1 signaling in the pathogenesis of liver disease and cancer caused by NEMO ablation in LPCs.
RESULTS

Inhibition of NF-kB Signaling in LPCs Does Not Phenocopy NEMO Deficiency
To study whether NEMO deficiency triggered hepatitis and HCC by inhibiting NF-kB, we generated and analyzed mice lacking NF-kB subunits in LPCs ( Figures 1A and 1B) . As reported previously (Geisler et al., 2007; Luedde et al., 2008) , RelA LPC-KO mice did not develop considerable liver pathology, although they had slightly elevated alanine aminotransferase (ALT) levels compared to wild-type mice at the age of 8 weeks ( Figure 1C ). To assess possible functional redundancy between NF-kB factors, we generated mice with LPC-specific single or combined deficiency of RelA, RelB, and c-Rel, hereafter referred to as NF-kB LPC-KO .
To address the role of hepatocyte NF-kB signaling in protecting the liver from endotoxin-induced injury, we compared the response of NF-kB LPC-KO and NEMO LPC-KO mice to a dose of LPS that does not induce considerable liver damage in wildtype mice. RelA/c-Rel LPC-KO and triple NF-kB LPC-KO mice showed increased serum ALT levels after LPS injection compared to RelA LPC-KO animals, suggesting that c-Rel can partly substitute pro-survival functions of RelA in hepatocytes ( Figure 1D ). However, NEMO LPC-KO mice were considerably more sensitive to endotoxin-induced liver damage showing $8-fold higher ALT levels compared to NF-kB LPC-KO animals.
(D) Graph depicting serum ALT levels in mice with the indicated genotypes before and 4 and 10 hr after LPS injection (mean ± SD).
(E) Representative images of liver sections from 8-week-old mice with the indicated genotypes that are stained with H&E or immunostained with the indicated antibodies. Graphs depict quantification of indicated parameters (mean ± SD, n = 3-5 mice per genotype). Scale bars, 200 mm. See also Figure S1 . Figure 1E ). Interestingly, in contrast to the NEMO-deficient livers that showed widespread distribution of apoptotic hepatocytes throughout the liver parenchyma, the few apoptotic hepatocytes in the livers of NF-kB LPC-KO mice were localized mostly in the vicinity of focal inflammatory cell infiltrates ( Figure 1E ). mice showed a number of very small macroscopically visible steatotic nodules ( Figure 2A ). Accordingly, liver-to-body weight (LW/BW) ratio in NF-kB LPC-KO mice was similar to controls and significantly lower than that of NEMO LPC-KO mice ( Figure 2B ).
One-year-old NF-kB LPC-KO mice showed significantly elevated serum ALT levels compared to controls but on average lower than NEMO LPC-KO mice ( Figure 2C ). Notably, ALT levels in NF-kB LPC-KO mice with macroscopically visible liver nodules were statistically higher compared to nodule-free mice (Figure 2C; 332 versus 135, p = 0.003) , indicating that the appearance of small steatotic nodules correlated with increased liver damage.
Histologically, livers from 1-year-old NF-kB LPC-KO mice showed a relatively normal overall architecture without signs of HCC or preneoplastic lesions, with the macroscopically visible nodules identified as focal fatty changes resembling clear cell foci ( Figures 2D, S2A , and S2B). Interestingly, collagen staining by Masson's trichrome showed that two-thirds of the examined livers (n = 9) displayed periportal or bridging fibrosis ( Figures 2D  and S2A ). The areas of focal apoptosis observed in the liver of 8-week-old mice were also present at 1 year of age ( Figures  2D, S2C , and S2D), but with higher frequency reflecting their increased serum ALT values ( Figure 2C ). Hepatocyte proliferation was mildly elevated in NF-kB LPC-KO mice compared to NF-kB FL littermates but lower than the non-tumor liver tissue of NEMO LPC-KO mice ( Figure 2D ). Therefore, combined ablation of RelA, RelB, and c-Rel in LPCs was not sufficient to cause spontaneous development of HCC as observed in NEMO LPC-KO mice, suggesting that NEMO prevents liver tumorigenesis by functions independent of NF-kB-mediated gene transcription.
Constitutively Active IKK2 Expression Prevents Hepatocellular Damage and HCC in NEMO LPC-KO Mice by
Activating NF-kB Although NF-kB inhibition alone was not sufficient to cause liver tumors, impairment of NF-kB could contribute to the liver pathology of NEMO LPC-KO mice when combined with the loss of NF-kB-independent NEMO functions. To address this possibility, we examined whether enforced NF-kB activation in NEMO-deficient hepatocytes induced by the overexpression of a constitutively active IKK2 (IKK2ca) transgene (Sasaki et al., 2006) mice. NEMO-deficient, but not NF-kB-deficient, primary hepatocytes underwent spontaneous apoptosis in culture that could be prevented by treatment with z-VAD-fmk and was only partially reduced by TNF blockade ( Figure S4B ). Consistent with its protective effect in vivo, IKK2ca expression prevented the spontaneous death of primary NEMO-deficient hepatocytes in vitro ( Figure S4B ). Assessment of NF-kB activation in z-VAD-fmktreated primary hepatocytes confirmed that IKK2ca induced constitutive nuclear accumulation of RelA ( Figure S4C ), suggesting that RelA-mediated expression of anti-apoptotic genes could prevent the death of NEMO-deficient hepatocytes. To address this possibility, we generated and analyzed NEMO and NF-kB LPC-KO mice ( Figure 4F ). These results suggested that apoptosis of NEMO-deficient hepatocytes is not caused by an impaired transcriptional regulation of NF-kB-dependent antiapoptotic genes, consistent with the findings that complete NF-kB inhibition did not phenocopy NEMO deficiency in the liver. However, IKK2ca expression induced elevated mRNA expression of the anti-apoptotic proteins cIAP1, cIAP2, and A20, as well as of the anti-oxidant enzyme SOD2 in NEMO-deficient livers ( Figure 4F ). Curiously, IKK2ca did not increase the mRNA expression of cFLIP and Bcl-xl that are considered important transcriptional targets of NF-kB ( Figure 4F ). In addition, IKK2ca reduced the expression of the proapoptotic protein Bax, which is expressed at increased levels in NEMO-deficient livers. These results suggested that IKK2ca expression prevents the death of NEMO-deficient hepatocytes by inducing NF-kB-dependent expression of anti-apoptotic and anti-oxidant genes. NEMO-deficient hepatocytes did not show TNF-inducible nuclear translocation of RelA but displayed strongly increased constitutive nuclear accumulation of p50 ( Figure S4C ). Moreover, RelB was constitutively present in the nucleus of NEMOdeficient hepatocytes at levels similar to those induced by TNF in wild-type cells ( Figure S4C ). This correlated with a decreased expression of cIAP1, whose degradation promotes non-canonical NF-kB activation (Sun, 2012 Figure S5A and data not shown). In addition, macroscopic and histological analysis of livers from 1-year-old mice revealed that RIPK3 deficiency did not prevent the development of HCC in NEMO LPC-KO mice ( Figures  S5B-S5E) . Therefore, RIPK3-dependent necroptosis does not contribute to the spontaneous liver pathology of NEMO LPC-KO mice.
Inhibition of RIPK1 kinase activity by necrostatin-1 or other small molecule inhibitors prevents RIPK3/MLKL-dependent necroptosis and under certain conditions apoptosis (Christofferson et al., 2014; Pasparakis and Vandenabeele, 2015; Vanden Berghe et al., 2014) . To address the role of RIPK1 kinase activity in hepatocyte death and HCC development in NEMO LPC-KO mice, we crossed them to knock-in mice expressing a kinaseinactive mutant RIPK1 (RIPK1D138N) mice showed strongly reduced serum ALT levels compared to NEMO LPC-KO mice ( Figure 5A ). Immunoblot analysis showed lack of caspase-3 and JNK activation in liver extracts from 8-week-old NEMO LPC-KO ;Ripk1 D138N/D138N mice ( Figure 5B ).
Accordingly, histological analysis of livers from NEMO LPC-KO ; Ripk1 D138N/D138N mice showed significantly reduced hepatocyte apoptosis and proliferation and HSC activation compared to NEMO LPC-KO mice ( Figure 5C ). To exclude the possibility that inhibition of RIPK1 kinase activity in a cell type different from LPCs was responsible for the protective effect, we generated NEMO Figure 5A and data not shown). Collectively, these results showed that lack of RIPK1 kinase activity strongly protected NEMO-deficient hepatocytes from apoptosis. To further dissect the role of the kinase activity-dependent and scaffolding functions of RIPK1 in hepatocyte death, we generated mice lacking both NEMO and RIPK1 Figure 5A ). Accordingly, liver extracts from NEMO LPC-KO ; RIPK1 LPC-KO mice showed activation of caspase-3 albeit at reduced levels compared to NEMO LPC-KO mice ( Figure 5B ). In addition, histological analysis showed substantial hepatocyte apoptosis and proliferation, inflammation and HSC activation in the liver of NEMO LPC-KO ;RIPK1 LPC-KO mice ( Figure 5C ). RIPK1 LPC-KO mice did not show considerable liver damage and displayed marginally elevated serum ALT levels and only sparse focal hepatocyte apoptosis, suggesting that the liver damage in NEMO LPC-KO ;RIPK1 LPC-KO is caused by the lack of NEMO and not RIPK1 (Figures 5A and S5F ).
In line with the reduced hepatocyte apoptosis in young mice, 1-year-old NEMO LPC-KO ;Ripk1 D138N/D138N or NEMO LPC-KO ; RIPK1
LPC-KO/D138N mice did not show macroscopic signs of liver tumor development (Figures 6A-6C) . Histological examination 
(legend continued on next page)
confirmed the lack of HCC or pre-neoplastic lesions and only 23% of the livers examined exhibited areas with clear cell foci and anisokaryosis ( Figures 6D and 6E) . Interestingly, although the livers of NEMO LPC-KO ;Ripk1 D138N/D138N did not show HSC activation at 8 weeks, they exhibited mild portal fibrosis with septa formation at the age of 1 year ( Figure 6D ). Analysis of 1-year-old NEMO LPC-KO ;RIPK1 LPC-KO mice revealed the development of liver tumors with dysplastic foci, dysplastic nodules and HCC, although macroscopically $33% of the mice analyzed (7 out of 20) had smaller nodules compared to NEMO LPC-KO mice suggesting that RIPK1 deficiency inhibited tumor growth (Figures 6A-6E) . Therefore, lack of RIPK1 kinase activity but not the absence of RIPK1 protein prevented hepatocyte apoptosis and HCC development in NEMO LPC-KO mice.
TRADD Mediates Apoptosis of NEMO-Deficient Hepatocytes in the Absence of RIPK1
The differential effects of RIPK1 kinase activity inhibition versus loss of its scaffolding functions suggested the existence of two distinct pathways triggering hepatocyte death in NEMO-deficient hepatocytes. When RIPK1 is present, its kinase activity is required for hepatocyte apoptosis, but when RIPK1 protein is absent, an alternative RIPK1-independent apoptotic pathway is induced. Since TRADD was shown to induce RIPK1-independent apoptosis (Vanlangenakker et al., 2011; Zheng et al., 2006) , we examined the role of TRADD in NEMO LPC-KO mice by generating mice lacking both NEMO and TRADD in LPCs ( Figure S6A ). Analysis of serum ALT levels at the age of 8 weeks showed that LPC-specific TRADD deficiency did not prevent hepatocyte death and hepatitis in NEMO LPC-KO mice ( Figure S6B ). Furthermore, macroscopic and histological examination of livers from 1-year-old NEMO LPC-KO ;TRADD LPC-KO mice revealed the development of HCC or pre-neoplastic lesions, although the number of macroscopically visible large tumors was decreased compared to littermates that were heterozygous for TRADD (Figures S6B-S6G ). Therefore, TRADD deficiency did not prevent hepatocyte apoptosis and liver damage but partly inhibited liver tumor growth in NEMO LPC-KO mice.
To assess whether TRADD triggers apoptosis in NEMO/RIPK1-deficient hepatocytes, we generated NEMO mice showed that apoptosis, compensatory proliferation, HSC activation and hepatitis were all nearly completely restored back to wild-type levels ( Figure 7C) 7D-7F) . Therefore, in the absence of RIPK1 scaffolding function, TRADD-mediated apoptosis induces liver damage and HCC development in NEMO LPC-KO mice.
RIPK1 and TRADD are known to induce apoptosis downstream of TNFR1 via distinct protein complexes suggesting that TNF might contribute to hepatocyte apoptosis in NEMO LPC-KO mice. However, we showed previously that LPC-specific ablation of TNFR1, Fas or TRAIL alone or in combination did not prevent hepatocyte death and HCC development in NEMO LPC-KO mice, arguing that apoptosis of NEMO-deficient hepatocytes is not triggered by these death receptors (Ehlken et al., 2014) . Furthermore, in contrast to a recent report (Cubero et al., 2013) , we found that TNFR1 deficiency did not considerably diminish liver damage in 8-week-old NEMO LPC-KO ;Tnfr1 À/À mice ( Figures S6H-S6K ).
One-year-old NEMO LPC-KO ;Tnfr1 À/À mice had mildly reduced ALT levels and LW/BW ratio compared to NEMO LPC-KO ; Tnfr1 WT/-, and they developed a similar number of dysplastic nodules although they lacked large tumors with histological characteristics of HCC ( Figures S6I-S6L ). Therefore, global TNFR1 deficiency did not prevent hepatocyte death and tumor initiation but delayed tumor progression in NEMO LPC-KO mice.
These results show that TNF is not an essential driver of hepatocyte apoptosis and tumor development in NEMO LPC-KO mice and suggest that other, yet unidentified, TNF-independent pathways trigger this liver pathology.
NEMO Prevents the Formation of a RIPK1/FADD/ Caspase-8 Complex in Hepatocytes
To gain mechanistic insight on how NEMO regulates RIPK1 kinase-mediated apoptosis, we analyzed the expression of proteins regulating the formation of the FADD/caspase-8 signaling complexes in NEMO LPC-KO mice. Expression of cFLIP, cIAP1, and TRAF2 was considerably diminished in NEMO-deficient livers and hepatocytes ( Figures 8A and 8B) . Notably, expression of kinase inactive RIPK1D138N, but not RIPK1 ablation, fully restored the expression of cFLIP and partly normalized the expression of TRAF2 and cIAP1 proteins in the NEMO-deficient livers ( Figures 8A and 8B) . Moreover, IKK2ca expression restored the protein levels of cIAP1 and SOD2 in NEMO-deficient livers ( Figures 8C and S4C) . Loss of cFLIP, cIAP1, and TRAF2 could trigger apoptosis in NEMO-deficient hepatocytes by promoting the association of RIPK1 with FADD and caspase-8, as shown for ripoptosome formation in response to DNA damage (Tenev et al., 2011) . Indeed, immunoprecipitation of RIPK1 and subsequent immunoblotting with antibodies against FADD and caspase-8 revealed that these proteins interacted with RIPK1 in NEMO-deficient hepatocytes ( Figure 8D ). Immunoprecipitation of FADD confirmed the interaction of RIPK1 with FADD and caspase-8 in NEMO-deficient hepatocytes ( Figure 8E ). Importantly, expression of kinase inactive RIPK1D138N prevented the association of FADD and caspase-8 with RIPK1 in NEMO-deficient hepatocytes ( Figures 8D and 8E Figure S4 . Graphs depict quantification of the indicated parameters (mean ± SD, n = 3-5 mice per genotype). Scale bar, 200 mm.
(legend continued on next page)
by preventing the formation of a RIPK1/FADD/caspase-8 apoptosis-inducing complex.
DISCUSSION
The IKK/NF-kB signaling pathway has emerged as a key regulator of liver homeostasis and disease. In particular, the finding that mice with LPC-specific NEMO deficiency showed spontaneous hepatocyte apoptosis, chronic hepatitis and HCC suggested a key function of NF-kB in preventing hepatocyte death in the adult liver and development of liver cancer (Luedde et al., 2007; Pasparakis, 2009) . To overcome the functional redundancy between NF-kB subunits, we studied the role of NF-kB in the adult liver by generating mice with LPC-specific ablation of all three NF-kB proteins capable of activating gene transcription, namely RelA, c-Rel, and RelB, thereby completely inhibiting NF-kB-mediated gene expression. Surprisingly, in contrast to NEMO LPC-KO mice, NF-kB LPC-KO mice showed only limited spontaneous hepatocyte apoptosis at young age and although a fraction of these mice showed increased liver damage, hepatitis, steatosis, and fibrosis at the age of 1 year they did not develop liver tumors. NEMO LPC-KO mice showed much more severe liver damage compared to NF-kB LPC-KO mice both spontaneously and in response to LPS, demonstrating that NEMO exhibits additional NF-kB-independent pro-survival functions in hepatocytes. Considering that NF-kB inhibition did not phenocopy NEMO deficiency, it was unexpected that overexpression of IKK2ca could prevent hepatocyte death and HCC development in NEMO LPC-KO mice. Our results that the IKK2ca protective effect largely depended on RelA suggested that IKK2ca prevented apoptosis of NEMO-deficient hepatocytes, at least in part, by inducing the NF-kB-dependent expression of pro-survival genes such as cIAP1, cIAP2, and A20. Moreover, IKK2ca expression also restored the expression of SOD2, which could protect NEMO-deficient hepatocytes from oxidative stress. Collectively, these results showed that NEMO ablation in LPCs triggers spontaneous hepatocyte death, chronic hepatitis, and HCC by inhibiting both NF-kB-dependent and NF-kB-independent pro-survival functions.
We showed previously that LPC-specific ablation of either IKK2 or IKK1 did not cause spontaneous liver pathology, but mice with combined IKK1/IKK2 or NEMO/IKK1 deficiency in LPCs developed severe jaundice and fatal cholangitis characterized by inflammatory destruction of small portal bile ducts, suggesting that combined inhibition of canonical and non-canonical NF-kB signaling resulted in cholestatic liver disease (Luedde et al., 2008) . However, NF-kB LPC-KO and NEMO LPC-KO ; RelB LPC-KO mice did not develop a similar biliary phenotype, suggesting that NF-kB-independent functions of IKK subunits control bile duct integrity in the liver. Our results revealed important but opposing RIPK1 kinasedependent and -independent functions in regulating liver disease in NEMO LPC-KO mice. Genetic inhibition of RIPK1 kinase activity strongly reduced hepatocyte death, thereby preventing liver damage and HCC development in NEMO LPC-KO mice. RIPK1 kinase activity induces both apoptosis and necroptosis (Pasparakis and Vandenabeele, 2015) . However, RIPK3 deficiency did not prevent hepatitis and HCC development in NEMO LPC-KO mice, arguing that RIPK3/MLKL-driven necroptosis does not play an important role in this model. Moreover, most dying hepatocytes in NEMO LPC-KO mice stain positive for active caspase-3 and ablation of FADD or caspase-8 strongly inhibited hepatocyte death and prevented HCC development in these mice (Ehlken et al., 2014; Liedtke et al., 2011; Luedde et al., 2007) . Together, these results show that RIPK1-mediated hepatocyte apoptosis causes chronic liver disease and HCC in NEMO LPC-KO mice. However, RIPK1 ablation could not prevent the death of NEMO-deficient hepatocytes showing that kinaseindependent scaffolding properties of RIPK1 are required to prevent hepatocyte apoptosis. Remarkably, combined LPCspecific deficiency of RIPK1 and TRADD, but not of TRADD alone, prevented hepatocyte apoptosis and HCC development in NEMO LPC-KO animals. RIPK1 and TRADD have been suggested to trigger TNFR1-mediated apoptosis via distinct signaling complexes, the TRADD-dependent complex IIa and the RIPK1-dependent complex IIb (Christofferson et al., 2014; Vanden Berghe et al., 2014; Wang et al., 2008) . Although TNFR1 deficiency did not prevent liver damage in NEMO LPC-KO mice, it remains unclear whether TNFR1 signaling might contribute to TRADD-dependent hepatocyte death in mice lacking both NEMO and RIPK1 in LPCs. NEMO-deficient as well as NF-kB-deficient livers did not show considerably reduced transcription of anti-apoptotic genes, revealing that NF-kB-dependent transcriptional regulation is not essential to protect the adult liver under physiological conditions. However, NEMO deficiency resulted in reduced protein expression of cFLIP, cIAP1, and TRAF2 suggesting that NEMO inhibits hepatocyte apoptosis, at least in part, by preventing the degradation of these anti-apoptotic proteins. Furthermore, immunoprecipitation experiments revealed that a RIPK1/ FADD/Caspase-8 signaling complex formed spontaneously in NEMO-deficient hepatocytes. Remarkably, expression of kinase inactive RIPK1D138N prevented the degradation of cFLIP, cIAP1, and TRAF2 and the formation of the RIPK1/FADD/Caspase-8 complex in NEMO-deficient livers. Single or combined knockout of TNFR1, Fas or TRAILR1 did not prevent liver damage and tumor development in NEMO LPC-KO mice (Ehlken et al., 2014) , suggesting that alternative signals drive the formation of the RIPK1/FADD/caspase-8 apoptosis-inducing complex in NEMO-deficient hepatocytes. It is tempting to speculate that loss of cIAPs and cFLIP may lead to the assembly of a complex resembling the ripoptosome, which forms in response to DNA damage or SMAC-mimetic-induced cIAP degradation (Tenev et al., 2011) . Ripoptosome formation was negatively regulated by cFLIP and required RIPK1 kinase activity, further supporting that similar mechanisms may trigger the formation of the RIPK1/FADD/caspase-8 complex inducing hepatocyte apoptosis in NEMO LPC-KO mice. However, it remains unclear by the ablation of FADD (Ehlken et al., 2014; Luedde et al., 2007) but not of RIPK1 (this study). Additionally, inhibition of RIPK1 kinase activity by Nec-1 did not inhibit TNF-induced apoptosis but prevented TNF+z-VAD-fmk-induced necroptosis of NEMO-deficient Jurkat cells (O'Donnell et al., 2012) . In contrast, we showed that inhibition of RIPK1 kinase activity prevented hepatocyte apoptosis in NEMO LPC-KO mice, while necroptosis does not play a role in this model. Therefore, different mechanisms regulate the TNF-induced death of NEMO-deficient Jurkat T cells in vitro and apoptosis of NEMO-deficient hepatocytes in vivo. Collectively, our results suggest that the interplay between NEMO, RIPK1, and NF-kB determines the survival or death of hepatocytes ( Figure 8F ). In wild-type livers, NEMO prevents hepatocyte apoptosis by inhibiting the formation of the deathinducing RIPK1/FADD/Caspase-8 signaling complex (complex IIb) . This function of NEMO is likely mediated, at least partly, by preventing the RIPK1 kinase activity-dependent degradation of cIAPs, TRAF2, and cFLIP. In addition, NEMO-mediated NF-kB-dependent expression of SOD2 could also contribute to the anti-apoptotic effect by reducing oxidative stress, as feeding with the anti-oxidant butylated hydroxyanisole reduced liver damage in NEMO LPC-KO mice (Luedde et al., 2007) . In the absence of NEMO, the RIPK1/FADD/Caspase-8 complex forms in a RIPK1 kinase activity-dependent manner and induces apoptosis. Enforced activation of NF-kB prevents apoptosis of NEMO knockout hepatocytes most likely by inducing the expression of pro-survival genes, such as cIAPs, A20, and SOD2. Lack of RIPK1 kinase activity prevents apoptosis of NEMO knockout hepatocytes by inhibiting the formation of the RIPK1/FADD/Casp8 complex. However, lack of RIPK1 protein removes not only its kinase-dependent but also its scaffolding functions, which are important to prevent degradation of cFLIP, cIAPs, and TRAF2, thereby promoting the formation of the TRADD/FADD/Casp8 complex (complex IIa) inducing apoptosis of NEMO-deficient hepatocytes. Taken together, our results identify a NF-kB-independent function of NEMO in controlling RIPK1 kinase activity-dependent apoptosis of hepatocytes that is critical to prevent chronic liver damage and HCC development in mice. These results suggest that the interplay between NEMO and RIPK1 could be implicated in chronic hepatitis and hepatocarcinogenesis in humans. Interestingly, a recent study reported loss of NEMO immunoreactivity in a significant percentage of human HCC samples, which correlated with a poor 5-year overall survival (Aigelsreiter et al., 2012) . These findings suggest that loss of NEMO-dependent cytoprotective functions may be critical for the development of chronic liver damage and HCC in at least a subset of patients. Hepatocyte death is a key feature of many chronic liver diseases, leading to inflammation, fibrosis, cirrhosis, and HCC development (Luedde et al., 2014) . Our results identify RIPK1 kinase activity as a potent trigger of hepatocyte apoptosis that causes chronic liver disease culminating in the development of HCC. Although the role of RIPK1 in human liver disease remains unclear, it is possible that RIPK1 kinase activity triggers hepatocyte death in at least a subset of patients with chronic liver diseases leading to HCC, such as viral hepatitis, alcoholic and non-alcoholic steatohepatitis. Our results suggest that RIPK1 kinase inhibitors could provide an effective and likely well-tolerated treatment option for such patients.
EXPERIMENTAL PROCEDURES Mice
The following mouse lines were used: Rela/p65 FL (Luedde et al., 2008) (Sasaki et al., 2006) , Alfp-Cre (Kellendonk et al., 2000) , Tradd FL (Ermolaeva et al., 2008) , Ripk3 À/À (Newton et al., 2004) , , Ripk1 FL (Dannappel et al., 2014) , and Tnfr1 À/À (Pfeffer et al., 1993) . All alleles were maintained on a C57BL/6 genetic background. Littermates carrying the floxed alleles but not the Alfp-Cre transgene served as controls. Animals were housed in individually ventilated cages in a specific pathogen-free (SPF) mouse facility at the Institute for Genetics, University of Cologne, kept under a 12-hr light cycle, and given a regular chow diet (Harlan, diet no. 2918) and water ad libitum. All animal procedures were conducted in accordance with European, national and institutional guidelines and protocols and were approved by local government authorities (Landesamt fü r Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Germany).
Mouse Experiments
LPS injections were performed on mice between 8 and 10 weeks of age. LPS (Sigma) was administered intraperitoneally, at a concentration of 25 mg/10 g of body weight, and blood was obtained prior to and 4 and 10 hr post injection. ALT levels were measured in serum using a Cobas c111 analyzer (Roche).
Histology, Immunohistochemistry, and Quantification H&E, Masson's trichrome staining, immunohistochemistry (IHC), and staining quantification was performed by standard procedures. For more detailed information, see the Supplemental Experimental Procedures.
Quantification of Macroscopically Visible Tumors and Histopathological Evaluation
Livers of 1-year-old mice were excised, digitally photographed with their dorsal side exposed, and weighed to calculate the liver/body weight ratio. The tumor number and size were determined by counting the number of visible tumors/nodules and measuring their diameter using ImageJ. Histopathological evaluation was performed as previously described (Ehlken et al., 2014) and explained in detail in the Supplemental Experimental Procedures.
Hepatocyte Isolation and Cell Death Assays
Primary hepatocytes were isolated from $4-week-old mice and cultured in DMEM (Sigma-Aldrich) containing 2% FCS, penicillin, and streptomycin. Cell death was estimated using an LDH release-based cytotoxicity assay (Promega) according to the manufacturers' instructions. For more detailed information, see the Supplemental Experimental Procedures. 
